SCHEMBL873241

SCHEMBL873241

Cc1ccc(NC(=O)[C@@H]2CCCN2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 3/20 0.55
SCN9A Q15858 2/20 0.55
PSMB8 P28062 2/20 0.54
DHODH Q02127 2/20 0.54
ULK1 O75385 1/20 0.50
KHK P50053 1/20 0.49
SCN5A Q14524 1/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
EPHX1 P07099 1/20 0.48
TERT O14746 1/20 0.47
PKM P14618 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PFKFB3 Q16875 3/20 0.46
PFKFB2 O60825 2/20 0.46
PFKFB1 P16118 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10327297 1.00 SCN3A (0.55) SCN3ASCN9APSMB8DHODHULK1
SCHEMBL17676974 1.00 SCN3A (0.55) SCN3ASCN9APSMB8DHODHULK1
SCHEMBL24609551 0.88 SCN3A (0.55) SCN3ASCN9APSMB8DHODHULK1
SCHEMBL7198731 0.87 LMNA (0.61) PKMPOLBMAPTSMN1; SMN2
SCHEMBL13388756 0.87 SCN3A (0.64) SCN3ASCN9APSMB8DHODHULK1
SCHEMBL29365790 0.86 SCN3A (0.56) SCN3ASCN9APSMB8DHODHULK1
SCHEMBL7692273 0.86 SCN3A (0.56) SCN3ASCN9APSMB8DHODHULK1
SCHEMBL13379539 0.84 SCN3A (0.58) SCN3ASCN9APSMB8DHODHULK1
SCHEMBL1750392 0.84 SCN3A (0.58) SCN3ASCN9APSMB8DHODHULK1
SCHEMBL1751199 0.84 SCN3A (0.55) SCN3ASCN9APSMB8DHODHULK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024197653-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) 2024-10-03 WO disclosed
WO-2023073115-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-04 WO disclosed
EP-2438989-B1 USE OF ASYMMETRIC HYDROGENATION CATALYST TAKASAGO PERFUMERY CO LTD (JP) 2016-04-13 EP disclosed
US-8399684-B2 Sulfonamide-based organocatalysts and method for their use STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) 2013-03-19 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-20100184986-A1 SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE The State of Oregon acting by and through the State Board of Higher Education on behalf of Orego 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184986-A1 SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE ALDH7A1, SULT1A1, SULT2A1 SCN3A 3398/4885SCN9A 1598/4885PSMB8 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.